breast cancer
Im EO, Chee W, Paul S, Choi MY, Kim SY, Yeo S, Ulrich CM, Schapira MM, Nguyen GT, Meghani S, Mao JJ, Ma G, Inouye[...]
Wu Y, Karapetyan E, Dutta P, Shaheen M, Vadgama JV. Inflammatory Cytokines Associated with Obesity, Type-2 Diabetes, and Hypertension Exacerbate Breast Cancer Risk in Underserved[...]
Daniel E, Deng F, Patel SK, Sedrak MS, Young J, Kim H, Razavi M, Sun CL, Root JC, Ahles TA, Dale W, Chen BT. Effect[...]
Ly D, Hoyt AC, Weimer A, Chang EH, Capiro N, Xie C, Chow L. Breast Cancer Among Transgender and Nonbinary Patients: Paradigms for Improving Data[...]
Katz S, Ciuba D, Ribas A, Shelach N, Zelinger G, Barrow B, Corn BW. A topical BRAF inhibitor (LUT-014) for treatment of radiodermatitis among women[...]
Hanalis-Miller T, Ricon-Becker I, Sakis N, Trachtenberg E, Ohayon F, Wadhawker S, Birnboim Y, Magen A, Sharon E, Tarrasch R, Goldzweig G, Cole SW, Jacoby[...]
Hamid A, Fonarow GC, Butler J, Hall ME. How do breast cancer clinical trials approach cardiovascular safety: targeted or generalized? Cardiooncology. 2024 Feb 7;10(1):6. doi:[...]
Glaspy J, Bondarenko I, Krasnozhon D, Rutty D, Chen J, Fu Y, Wang S, Hou Q, Li S. Efbemalenograstim alfa not inferior to pegfilgrastim in[...]
Glaspy J, Bondarenko I, Burdaeva O, Chen J, Rutty D, Li R, Wang S, Hou Q, Li S. Efbemalenograstim alfa, an Fc fusion protein, long-acting[...]
Ji J, Bae M, Sun CL, Wildes TM, Freedman RA, Magnuson A, O'Connor T, Moy B, Klepin HD, Chapman AE, Tew WP, Dotan E, Fenton[...]